Advaxis Inc. (ADXS) Trading Down 3.4%
Advaxis Inc. (NASDAQ:ADXS)’s share price dropped 3.4% during mid-day trading on Thursday . The company traded as low as $12.86 and last traded at $13.22, with a volume of 3,076,919 shares. The stock had previously closed at $13.69.
ADXS has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Advaxis in a report on Thursday, April 21st. FBR & Co reaffirmed an “outperform” rating and set a $34.00 price objective on shares of Advaxis in a report on Tuesday, May 17th. Jefferies Group reaffirmed a “buy” rating on shares of Advaxis in a report on Friday, June 10th. Finally, Barclays PLC lifted their price objective on shares of Advaxis from $15.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday. Six equities research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus target price of $25.80.
The firm has a 50-day moving average price of $8.41 and a 200 day moving average price of $8.05. The company’s market cap is $441.69 million.
In related news, Director Thomas J. Mckearn sold 4,100 shares of the firm’s stock in a transaction on Friday, May 13th. The stock was sold at an average price of $7.45, for a total value of $30,545.00. Following the completion of the sale, the director now owns 82,120 shares of the company’s stock, valued at $611,794. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.